Turner syndrome in childhood and adolescence

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 16, Issue 3, 2002, Pages 465-482

  Batch, Jennifer ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Adult care; Clinical features; Diagnosis; Growth; Growth hormone; Growth promoting therapy; Molecular genetics; Natural history; Oestrogen; Oxandrolone; Pubertal induction; Puberty; Side effects of treatment; Transition; Turner syndrome

Indexed keywords

ESTRADIOL; ESTROGEN; GROWTH HORMONE; OXANDROLONE; SOMATOMEDIN C;

ADOLESCENT; BODY HEIGHT; CHILD; CHILD GROWTH; CHROMOSOME DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; CLITORIS HYPERTROPHY; DELAYED PUBERTY; DOSE RESPONSE; DRUG POTENTIATION; ESTROGEN ACTIVITY; FEMALE; FERTILITY; GLUCOSE INTOLERANCE; HOMEOBOX; HUMAN; HYPERTENSION; INFANCY; MOLECULAR GENETICS; PREGNANCY; PREMATURE OVARIAN FAILURE; PSYCHOLOGICAL ASPECT; PUBERTY; REVIEW; SHORT STATURE; SIDE EFFECT; TURNER SYNDROME; VIRILIZATION; GROWTH ACCELERATION; GROWTH RATE; HORMONAL THERAPY; LEG LENGTHENING; PATIENT CARE; PERINATAL PERIOD; PHENOTYPE; PRENATAL CARE; TREATMENT OUTCOME; X CHROMOSOME;

EID: 0036960088     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1053/beem.2002.0217     Document Type: Review

References (118)

1. Ranke M & Saenger P. Turner syndrome. Lancet 2001; 350: 309-314.
2. Ulrich O. Uber typische Kombinacionsbilder multipler Abartung, Z Kinderheilkd 1930; 49: 271-276.
3. Turner H. A syndrome of infantilism, congenital wabbed neck and cubitus valgus. Endocrinol 1938; 23: 566-574.
4. Hsu L. Prenatal diagnosis of chromosomal abnormalities through amniocentesis. In: Milunsky A (ed.) Genetic Disorders and the Fetus, pp 179-248. Baltimore: John Hopkins University Press, 1998.
5. Rosenfeld R. Turner syndrome: A growing concern. Journal of Pediatrics 2001; 137: 443-444.
6. Machur A, Stekol L, Schatz D et al. The paternal origin of the single X chromosome in Turner syndrome: Lack of correlation with paternal age or clinical phenotype. American Journal of Human Genetics 1991; 48: 682-686.
7. Golbus M. Prenatal diagnosis and fetal loss. In: Rosenfeld R & Grumbach M (eds) Turner Syndrome, pp 101-108. New York: Marcel Dekker, 1990.
8. Gravholt C, Juul S, Naeraa R et al.. Prenatal and postnatal prevalence of Turner syndrome: A registry study. British Journal of Medicine 1996; 321: 16-21.
9. Koerbel D, McGillvray B & Sybert V. Prenatal diagnosis of 45X/46XX mosaicism and 45X: Implications for postnatal outcomes. American Journal of Human Genetics 1995; 57: 661-666.
10. Chang H, Clark B & Bachman H. The phenotype of 45,X/46,XY mosaicism: An analysis of 92 practically diagnosed cases. American Journal of Human Genetics 1990; 46: 156-167.
11. Verp M & Simpson J. Abnormal sexual differentiation and neoplasia. Cancer Genetics and Cytogenetics 1987; 25: 191-218.
12. Gravholt C, Fedder J, Naeraa R et al. Occurrence of gonadoblastoma in females with Turner syndrome and Y chromosome material - A population study. Journal of Clinical Endocrinology and Metabolism 2000; 85: 3199-3202.
13. Saenger P, Albertsson-Wikland K, Conway G et al. Recommendations for the diagnosis and management of Turner syndrome. Journal of Clinical Endocrinology and Metabolism 2001; 86: 3061-3069.
14. Roa E, Weiss B, Fukami M et al. Pseudoautosomal deletions encompassing a novel homebox gene cause growth failure in idiopathic short stature and Turner syndrome. Nature Genetics 1997; 16: 54-63.
15. Belin V, Cusin V, Viot G et al. SHOX mutations in dyschondrosteosis (Leri-Weill syndrome). Nature Genetics 1998; 19: 67-69.
16. Clement-Jones J, Schiller S, Rao E et al. The short stature homeobox gene (SHOX) is involved in skeletal abnormalities in Turner syndrome. Human Molecular Genetics 2000; 9: 695-702
17. Schiller S, Spranger S, Schochinger B et al. Phenotypic variation and genetic heterogeneity in Leri-Weill syndrome. European Journal of Human Genetics 2000; 8: 54-62.
18. Ballabio A & Andria G. Deletions and translocations involving the distal short arm of the human X chromosome: Review and hypotheses. Human Molecular Genetics 1992; 1: 221-227.
19. Kosho T, Muroya K, Nagai I et al. Skeletal features and growth patterns in 14 patients with haploinsufficiency of SHOX: Implications for the development of Turner syndrome. Journal of Clinical Endocrinology and Metabolism 1999; 84: 4613-4621.
20. Zinn A & Ross J. Critical regions for Turner syndrome phenotypes on the X chromosome. In Saenger P & Pasquino A (eds) Optimising Health Care for Turner Patients in the 21st Century, pp 19-28. Amsterdam: Elsevier, 2000.
21. Ogata T, Muroya K & Matsuo N. Structure function relation of the X chromosome in Turner syndrome. In Saenger P & Pasquino A (eds) Optimising Health Care for Turner Patients in the 21st Century, pp 9-18. Amsterdam: Elsevier, 2000.
22. Ogata T & Matsuo N. Sex chromosome aberrations and stature deductions of the principal factors involved in the determination of adult height. Human Genetics 1993; 91: 551-562.
23. Saenger P. Turner syndrome. New England Journal of Medicine 1996; 335: 1749-1754.
24. Binder H, Fritsch H, Schweizer R et al. Radiological signs of Leri-Weill dyschondrosteosis in Turner syndrome. Hormone Research 2001; 55: 71-76.
25. Ross J, Scott C, Marttila P et al. Phenotype associated with SHOX deficiency. Journal of Clinical Endocrinology and Metabolism 2001; 86: 5674-5680.
26. Lippe B. Turner syndrome. Endocrinology and Metabolism Clinics of North America 1991; 20: 121-152.
27. Stenberg A, Nylen O, Windh M et al. Otological problems in children with Turner syndrome. Hearing Research 1998; 124: 85-90.
28. Elsheikh M, Conway G & Wass J. Medical problems in adult women with Turner syndrome. Annals of Medicine 1999; 31: 99-105.
29. Barrenas M, Landin-Wilhelmsen K & Hanson C. Ear and hearing in relation to genotype and growth in Turner syndrome. Hearing Research 2000; 144: 21-28.
30. Van Borse J, Dhooge I, Verhoye K et al. Communication problems in Turner syndrome: A sample survey. Journal of Communication Disorders 1999; 32: 435-444.
31. Sybert V. Cardiovascular malformations and complications in Turner syndrome. Pediatrics 1998; 101: E11.
32. Nagel T & Tesch L. ART and the high risk patient. Fertility and Sterility 1997; 68: 748-749.
33. Radetti G, Mazzanti L, Paganini C et al. Frequency, clinical and laboratory features of thyroiditis in girls with Turner syndrome. The Italian Study Group for Turner Syndrome. Acta Paediatrica 1995; 84: 909-912.
34. Wilson D, Frane J, Sherman B et al. Carbohydrate and lipid metabolism in Turner syndrome effect of therapy with growth hormone, oxandrolone and a combination of both. Journal of Pediatrics 1988; 112: 210-217.
35. Rovet J. The psychoeducational characteristics of children with Turner syndrome. Journal of Learning Disabilities 1993; 26: 333-341.
36. Ross J, Kushner H & Roeltgen D. Developmental changes in motor function in girls with Turner syndrome. Pediatric Neurology 1996; 15: 317-322.
37. Ross J, Roeltgen D, Feuillan P et al. Use of oestrogen in young girls with Turner syndrome: Effects on memory. Neurology 2000; 54: 164-170.
38. McCauley E, Kay T, Ito J et al. The Turner syndrome: Cognitive deficits affective discrimination and behavioural problems. Child Development 1987; 5: 464-473.
39. Sato H, Miyamoto S & Sasaki N. Liver abnormalities in Turner syndrome. European Journal of Paediatrics 2001; 160: 59.
40. Larizzi D, Locatelli M, Vitalli L et al. Serum liver enzymes in Turner Syndrome. European Journal of Pediatrics 2000; 159: 143-148.
41. Gillett P, Gillet H, Israel D et al. Increased prevalence of celiac disease in girls with Turner syndrome detected using antibodies to endomyslum and tissue transglutaminase. Canadian Journal of Gastroenterology 2000; 14: 915-918.
42. Ruiz C. Turner syndrome and multiple marker screening. Clinical Chemistry 1999; 45: 2259-2261.
43. Zinn A & Page D. Turner syndrome and the Y chromosome. In: Hibi I & Takano K (eds) Basic and Clinical Approach to Turner Syndrome, pp 49-56. Amstermdam: Elsevier, 1993.
44. Massa G & Vanderschueren-Lodeweyckx M. Age and height at diagnosis in Turner syndrome: Influence of parental height. Pediatrics 1991; 88: 1148-1152.
45. Savendahl L & Davenport M. Delayed diagnosis of Turner syndrome: Proposed guidelines for change. Journal of Pediatrics 2000; 137: 455-459.
46. Lyon A, Preece M & Grant D. Growth curves for girls with Turner syndrome. Archives of Disease in Childhood 1985; 60: 932-935.
47. Karlberg J, Albertsson-Wikland K & Weis Naeraa R. The infancy-childhood-puberty (ICP) model of growth for Turner girls. Excerpta Medica 1991; 924: 89-94.
48. Ranke M. Growth disorder in the Ulrich-Turner syndrome. Baillière's Clinical Endocrinology and Metabolism 1992; 6: 603-619.
49. Ranke M, Stubbe P, Majewski F et al. Spontaneous growth in Turner syndrome. Acta Paediatrica Scandinavica 1988; 343 (supplement): 22-30.
50. Lippe B, Plotnick L, Attie K et al. Growth in Turner syndrome updating the United States experience. In: Hibi I & Takano K (eds) Basic and Clinical Approach to Turner Syndrome, pp 77-82. Amsterdam: Elsevier, 1993.
51. Rongen-Westerlaken C, Corel L, Van Den Broeck J et al. Reference values for height, height velocity and weight in Turner syndrome. Swedish Study Group for GH Treatment. Acta Paediatrics 1997; 86: 937-942.
52. Suwa S. Standard for growth and growth velocity in Turner Syndrome. Acta Paediatrica Japanica 1992; 34: 206-221.
53. Bernasconi S, Larizza D, Benso L et al. Turner syndrome in Italy: Familial characteristics, neonatal data and standards for birth weight and for height and weight from infancy to adulthood. Acta Paediatrica 1994; 83: 292-298.
54. Davenport M, Punyasavacsut N, Gunther D et al. Turner syndrome: A pattern of early growth failure. Acta Paediatrica 1999; 88: 118-121.
55. Karlberg J. A biologically oriented mathematical model (ICP) for human growth. Acta Paediatrica Scandinavica 1987; 350 (supplement): 70-84.
56. Even L, Cohen A, Marbach N et al. Longitudinal analysis of growth over the first 3 years of life in Turner syndrome. Journal of Pediatrics 2000; 137: 460-464.
57. Rutherford A & Matthews S. Cryopreservation of ova. In: Saenger P & Pasquino A (eds) Optimising Health Care for Turner Patients in the 21st Century. pp. 239-24. Amsterdam: Elsevier, 2000.
58. Singh R & Carr D. The anatomy and histology of XO human embryos and fetuses. Anatomical Record 1965; 155: 369-384.
59. Weiss L. Additional evidence of gradual loss of germ cells in the pathogenesis of streak ovaries in Turner syndrome. Journal of Medical Genetics 1971; 8: 540-544.
60. Pasquino A, Passeri F, Pucarelli I et al. Spontaneous pubertal development in Turner syndrome. Journal of Clinical Endocrinology and Metabolism 1997; 83: 1810-1813.
61. Naeraa R & Nielsen J. Standards for growth and final height in Turner syndrome. Acta Paediatrica Scandinavica 1990; 79: 182-190.
62. Stanhope R, Mossarano A & Brook C. Natural history of ovarian demise in Turner syndrome. In Hibi I & Takano K (eds) Basic and Clinical Approach to Turner Syndrome, pp 93-10. Amsterdam: Elsevier, 1993.
63. Conte P, Grumbach M & Kaplan S. A diphasic pattern of gonadotrophin secretion in patients with the syndrome of gonadal dysgenesis. Journal of Clinical Endocrinology and Metabolism 1975; 40: 670-674.
64. Suwa S, Maeska H & Matsui I. Serum LH and FSH responses to synthetic LH-RH in normal infants, children and patients with Turner syndrome. Pediatrics 1974; 54: 470-475.
65. Ross J, Loriaux D & Cutler G. Developmental changes in neuroendocrine regulation of gonadotrophin secretion in gonadal dysgenesis. Journal of Clinical Endocrinology and Metabolism 1983; 57: 288-293.
66. Samaan N, Stepanas A, Danziger J et al. Reactive pituitary abnormalities in patients with Klinefelter's syndrome. Archives of Internal Medicine 1979; 139: 198-201.
67. Apter D. Serum steroids and pituitary hormones in female puberty. Clinical Endocrinology (Oxford) 1980; 12: 107-120.
68. Apter D, Lenko H, Perheentupa J et al. Subnormal pubertal increases of serum androgens in Turner syndrome. Hormone Research 1982; 16: 164-173.
69. Ranke M & Grauer M. Adult height in Turner syndrome: Results of a multinational survey. Hormone Research 1993; 42: 90-94.
70. Wiedemann H & Glatzl J. Follow-up of Ullrich's original patient with 'Ullrich-Turner' syndrome. American Journal of Medical Genetics 1991; 41: 134-136.
71. Blethen S, Albertsson-Wikland K, Faklis E et al. Circulating growth hormone isoforms in girls with Turner syndrome. Journal of Clinical Endocrinology and Metabolism 1994; 78: 1439-1443.
72. Rose J, Long L, Loriaux D et al. Growth hormone secretory dynamics in Turner syndrome. Journal of Pediatrics 1985; 106: 202-206.
73. Lu PW, Cowell CT, Jimenez M et al. Effects of obesity on endogenous growth hormone secretion in Turner syndrome. Archives of Disease in Childhood 1991; 66: 1184-1190.
74. Albertsson-Wikland K & Rosberg S. Pattern of spontaneous growth hormone secretion in Turner syndrome. In Ranke M & Rosenfeld (eds) Turner Syndrome: Growth Promoting Therapies, Amsterdam: Elsevier, 1991.
75. Hochberg Z, Pollack S & Aviram M. Resistance to insulin like growth factor I in Turner syndrome. In Hibl I & Takano K (eds) Basic and Clinical Approach to Turner Syndrome, pp 233-237. Amsterdam: Elsevier, 1993.
76. Ross J, Long L, Skerda M et al. Effect of low doses of oestradiol on 6 month growth rates and predicted heights in patients with Turner syndrome. Journal of Pediatrics 1986; 109: 950-953.
77. Smith E, Boyd J, Frank G et al. Oestrogen resistance caused by a mutation in the oestrogen receptor gene in a man. New England Journal of Medicine 1994; 331: 1056-1061.
78. Johnston D, Betts P, Dunger D et al. A multicentre trial of recombinant growth hormone and low dose oestrogen in Turner syndrome: Near final height analysis. Archives of Disease in Childhood 2001; 84: 76-81.
79. Bettmann H, Goldmann H, Abramowitz M et al. Oxandrolone treatment of short stature: Effect on predicted mature height. Journal of Pediatrics 1971; 79: 1018-1023.
80. Joss E & Zuppinger K. Oxandrolone in girls with Turner syndrome: A pair matched controlled study up to final height. Acta Paediatrica Scandinavica 1984; 73: 674-679.
81. Urban M, Lee P, Dorst J et al. Oxandrolone therapy in patients with Turner syndrome. Journal of Pediatrics 1979; 94: 823-827.
82. Moore D, Tattoni D, Ruvalcaba R et al. Studies of anabolic steroids VI. Effects of prolonged administration of oxandrolone in children and adolescents with gonadal dysgenesis. Journal of Pediatrics 1977; 90: 462-466.
83. Sybert V. Adult height in Turner syndrome with and without androgen therapy. Journal of Pediatrics 1984; 104: 365-369.
84. Lev-Ran A. Androgens, oestrogens and the ultimate height in XO gonadal dysgenesis. American Journal of Diseases of Children 1977; 131: 648-649.
85. Rosenbloom A & Frias J. Oxandrolone for growth promotion in Turner syndrome. American Journal of Diseases of Children 1973; 125: 385-387.
86. Crack P, Werther G & Wertenhall H. Oxandrolone increases final height in Turner syndrome. Journal of Paediatrica and Child Health 1990; 26: 221-224.
87. Hutchings J, Escamillia R, Li C et al. Human growth hormone administration in gonadal dysgenesis. American Journal of Diseases of Children 1965; 109: 318-321.
88. Tanner J, Whitehouse R, Hughes P et al. Effect of human growth hormone treatment for 1-7 years on growth of 100 children with growth hormone deficiency, low birth weight, inherited smallness. Turner syndrome and other complaints. Archives of Disease in Childhood 1971; 46: 745-782
89. Tzagournis M. Response to long term administration of human growth hormone in Turner syndrome. Journal of the American Medical Association 1969; 210: 2373-2376.
90. Ranke M. Growth hormone therapy in Turner syndrome: Analysis of long term results. Hormone Research 1995; 44 (supplement 3): 35-41.
91. Rosenfeld R, Attle K, Frane J et al. Growth hormone therapy of Turner syndrome: Beneficial effect on adult final height. Journal of Pediatrics 1998; 132: 319-324.
92. Van Den Broeck J, Massa G, Attanasia A et al. Final height after long-term growth hormone treatment in Turner syndrome. Journal of Pediatrics 1995; 127: 729-735.
93. Nillson K, Albertsson-Wikland K, Alm J et al. Improved final height in girls with Turner syndrome treated with growth hormone and oxandrolone. Journal of Clinical Endocrinology and Metabolism 1996; 81: 635-640.
94. Carel J, Mathivon L, Gendrel C et al. Near normalisation of final height with adapted doses of growth hormone in Turner syndrome. Journal of Clinical Endocrinology and Metabolism 1998; 83: 1462-1466.
95. Sas T, De Muinck Keizer-Schrama S, Stijen T et al. Normalisation of height in girls with Turner syndrome after long term growth hormone treatment: Results of a randomised dose response trial. Journal of Clinical Endocrinology and Metabolism 1999; 84: 4607-4612.
96. Yu H, Spitz M, Mistry J et al. Plasma levels of insulin-like growth factor I and lung cancer. Journal of the National Cancer Institute 1999; 91: 151-156.
97. Tillman V, Patel L, Gill M et al. Monitoring serum insulin-like growth factor-1 (IGF-1), IGF binding protein 3 (IGFBP-3), IGF-1/IGFBP-3 makes mode and leptin during growth hormone treatment for disordered growth. Clinical Endocrinology (Oxford) 2000; 53: 329-336.
98. Ranke M, Lindberg A, Chatelain P et al. Prediction of long term response to recombinant human growth hormone (GH) in Turner syndrome: Development and validation of mathematical models. Journal of Clinical Endocrinology and Metabolism 2000; 85: 4212-4218.
99. Nasera R, Nielsen J & Kucrup K. Growth hormone and 17β-estradiol treatment of Turner girls - 2 year results. European Journal of Pediatrics 1993; 153: 72-77.
100. Igurashi Y, Ogawa E, Fulleda K et al. Treatment of Turner syndrome with transdermal 17β estradiol. In Hibi I & Takano K (eds) Basic and Clinical Approach to Turner Syndrome. pp 197-200 Amsterdam: Elsevier, 1993.
101. Charnock S, Aule K, Cara J et al. Growth hormone therapy of Turner syndrome: The impact of age of oestrogen replacement on final height. Journal of Clinical Endocrinology and Metabolism 2000; 814: 2439-2445.
102. Reicer E, Biernen S, Baptista J et al. Early initiation of growth hormone treatment allows age appropriate oestrogen use in Turner syndrome. Journal of Clinical Endocrinology and Metabolism 2001; 86: 1936-1941.
103. Sas I, De Muinck Keizer-Schrama S, Aanscoor H et al. Carbohydrate metabolism during growth hormone treatment and after discontinuation of growth hormone treatment in girls with Turner syndrome treated with once or twice daily growth hormone injections. Clinical Endocrinology 2000; 52: 741-747.
104. Sim Y, Willemjun M et al. Body proportions during long term growth hormone treatment in girls with Turner syndrome participating in a randomised dose response trial. Journal of Clinical Endocrinology and Metabolism 1999; 84: 4622-4628.
105. Saenger F, Wesely S, Glickstein J et al. No evidence for ventricular hypertrophy in Turner syndrome after growth hormone therapy. In: Albertsson-Wiklund K & Junke M (eds) Turner Syndrome in a Life Span Perspectives Research and Clinical Aspects, pp 259-262. Amsterdam: Elsevier, 1995.
106. Price D, Clayton P, Crowne E et al. Safety and efficacy of human growth hormone treatment in girls with Turner syndrome. Hormone Research 1993; 39 (supplement): 44-48.
107. Salerno M, Di Muio S, Ferri P et al. Liver abnormalities during growth hormone treatment. Journal of Pediatric Gastroenterology and Nutrition 2000; 31: 149-151.
108. Rogers A, Rogers G, Bremer D et al. Pseudotumour cerebral in children receiving recombinant human growth hormone. Ophthalmology 1999; 106: 1186-1190.
109. Wyace D. Melanocytic naevi in children treated with growth hormone. Pediatrics 1999; 104: 1045-1050.
110. Conway G. Oestrogen replacement in young women with Turner syndrome. Clinical Endocrinology 2001; 54: 157-158.
111. Hovarta O, Foudila T & Soderstrom-Antilla V. Assisted reproductive techniques in Turner syndrome. In Saenger P & Pasquino A (eds) Optimising Health Care for Turner Patients in the 21st Century, pp 247-253. Amsterdam, Elsevier 2000.
112. Grayhole C, Juul S, Naescaa R et al. Morbidity in Turner syndrome. Journal of Clinical Epidemiology 1997; 51: 146-158.
113. Nesty E, Marcus R, Rosenfield R et al. Turner syndrome adolescents receiving growth hormone are not osteoporotic. Journal of Clinical Endocrinology and Metabolism 1993; 76: 861-866.
114. Lanes R, Guncalcer P, Paoli M et al. Bone mineral density of prepubertal age girls with Turner syndrome while on growth hormone therapy. Hormone Research 1995; 44: 168-171.
115. Sas T, De Muinck Kaizer-Schreiner S, Sjogren T et al. A longitudinal study on bone density until adulthood in girls with Turner syndrome participating in a growth hormone injection frequency trial. Clinical Endocrinology (Oxford) 2000; 52: 531-536.
116. Ross J, Meyerson Long L, Fentillan P et al. Normal bone density of the wrist and spine and increased wrist fractures in girls with Turner syndrome. Journal of Clinical Endocrinology and Metabolism 1991; 73: 355-359.
117. Bachrach L. Routine monitoring of bone density is not warranted in patients with Turner syndrome. In Saenger P & Pasquino A (eds) Optimising Health Care for Turner Patients in the 21st Century, pp 267-273. Amsterdam: Elsevier, 2000.
118. Cowell C. Short stature. In Brook C (ed). Clinical Paediatric Endocrinology, pp 136-172. Oxford: Blackwell Science, 1995.